Longevity & AgingTirzepatide Lowers Adolescent BMI by 18.5% in Phase III Trial
Tirzepatide substantially reduced body mass index, or BMI, in adolescents with obesity or overweight and related health complications. In the phase III SURMOUNT-ADOLESCENTS trial, weekly treatment plus lifestyle support reduced average BMI by 18.5% over 72 weeks, compared with a 0.5% increase with placebo. More than half of treated participants fell below the clinical obesity threshold, and nearly half achieved a BMI reduction of at least 20%. Waist circumference, body weight, and physical functioning also improved. The findings suggest meaningful benefits for metabolic health and everyday function, but they do not establish longer life or lasting disease prevention. Families should discuss individualized treatment with a clinician rather than copy the trial’s dosing schedule. The supplied article is incomplete and does not provide essential safety details or participant numbers.